

Circulating metabolic biomarkers are consistently associated with incident type 2 diabetes in Asian and European populations – a metabolomics analysis in five prospective cohorts

Jowly Yi Hoong Seah^{1*}, Yueheng Hong^{1*}, Anna Cichońska^{2*}, Charumathi Sabanayagam^{3,4}, Simon Nusinovic³, Tien Yin Wong^{3,4,5}, Ching-Yu Cheng^{3,4,5}, Pekka Jousilahti⁶, Annamari Lundqvist⁶, Markus Perola^{6,7}, Veikko Salomaa⁶, E. Shyong Tai^{1,4,5}, Peter Würtz², Rob M. van Dam^{1,8†}, Xueling Sim^{1†}

¹Saw Swee Hock School of Public Health, National University of Singapore and National University Health System, Singapore; Singapore 117549, Singapore

²Nightingale Health Ltd, Mannerheimintie 164a, 00300 Helsinki, Finland

³Singapore Eye Research Institute, Singapore National Eye Centre, Singapore 169856, Singapore

⁴Duke-NUS Medical School, Singapore 169857, Singapore

⁵Yong Loo Lin School of Medicine, National University of Singapore and National University Health System, Singapore 117597, Singapore

⁶Department of Public Health Solutions, Finnish Institute for Health and Welfare, P.O. Box 30, FI-00271 Helsinki, Finland

⁷Research Program for Clinical and Molecular Metabolism, Faculty of Medicine, University of Helsinki, 00014 Helsinki, Finland.

⁸Departments of Exercise and Nutrition Sciences and Epidemiology, Milken Institute School of Public Health, The George Washington University, Washington, DC 20052.

*These authors contributed equally.

†These authors are co-corresponding senior authors.

Rob M. van Dam. Department of Exercise and Nutrition Sciences, Milken Institute
School of Public Health, The George Washington University, 950 New Hampshire
Ave NW, Washington, DC 20052; tel: +1 202 994 8490; e-mail: rvandam@gwu.edu
Xueling Sim. Saw Swee Hock School of Public Health, 12 Science Drive 2, #10-01,
Singapore 117549; tel: +65 6601 5096; e-mail: ephsx@nus.edu.sg

Number of figures (to print, not Supplementary data): 1

Number of tables (to print, not Supplementary data): 2

Supplementary data submitted: 6 tables

Running title: Metabolic biomarkers and type 2 diabetes

Abbreviations: ARIC, Atherosclerosis Risk in Communities, BCAA, branched-chain amino acids, BMI, body mass index, GlycA, glycoprotein acetyls, HbA1c, glycated hemoglobin, HDL, high-density lipoprotein, IDL, intermediate-density lipoprotein, LDL, low-density lipoprotein, MEC, Multiethnic Cohort, MUFA, monounsaturated fat, NMR, nuclear magnetic resonance, PUFA polyunsaturated fat, SEED, Singapore Epidemiology of Eye Diseases, SFA, saturated fat, T2D, type 2 diabetes, VLDL, very low-density lipoprotein

Word count: 4229 (Introduction to Discussion)

1 **Abstract**

2 Background: While Asians have a higher risk of type 2 diabetes (T2D) than
3 Europeans for a given BMI, it remains unclear whether the same markers of metabolic
4 pathways are associated with diabetes.

5 Objectives: We evaluated associations between metabolic biomarkers and incident
6 T2D in three major Asian ethnic groups (Chinese, Malay, and Indian) and a European
7 population.

8 Methods: We analyzed data from adult males and females of two cohorts from
9 Singapore (n = 6,393) consisting of Chinese, Malays and Indians, and three cohorts of
10 European-origin participants from Finland (n = 14,558). We used nuclear magnetic
11 resonance to quantify 154 circulating metabolic biomarkers at baseline and performed
12 logistic regression to assess associations with T2D risk adjusted for age, sex, BMI and
13 glycaemic markers.

14 Results: Of the 154 metabolic biomarkers, 59 were associated with higher risk of T2D
15 in both Asians and Europeans ($P < 0.0003$; Bonferroni-corrected). These included
16 branched-chain and aromatic amino acids, the inflammatory marker glycoprotein
17 acetyls, total fatty acids, monounsaturated fatty acids, apolipoprotein B, larger very
18 low-density lipoprotein particle sizes, and triglycerides. In addition, 13 metabolites
19 were associated with a lower T2D risk in both populations including omega-6
20 polyunsaturated fatty acids and larger high-density lipoprotein particle sizes.

21 Associations were consistent within the Asian ethnic groups (all $P_{\text{het}} \geq 0.05$) and
22 largely consistent for the Asian and European populations ($P_{\text{het}} \geq 0.05$ for 128 of 154
23 metabolic biomarkers).

24 Conclusion: Metabolic biomarkers across several biological pathways were
25 consistently associated with T2D risk in Asians and Europeans.

26

27 Keywords: NMR, metabolomics, type 2 diabetes, branched-chain amino acids,

28 aromatic amino acids, glycoprotein acetyls, inflammation, fatty acids, lipoprotein,

29 HDL, LDL, triglycerides, cholesterol

30

31 **Introduction**

32 The global burden of type 2 diabetes (T2D) is high and rising [1, 2], with the
33 prevalence expected to rise to 7079 cases per 100,000 in 2030, from 6059 cases per
34 100,000 in 2017 [2]. In randomized trials, pharmaceutical and lifestyle interventions
35 substantially reduced the risk of T2D [3-5] in high-risk individuals. Variation in
36 genetic, environmental and lifestyle exposures between individuals, coupled with
37 heterogeneity in T2D [6, 7] has motivated omics biomarkers as intermediate
38 phenotypes to T2D and the development of ‘precision medicine’ approaches to
39 prevention [8-10]. Metabolic biomarkers reflect the dynamic and ongoing state of
40 homeostasis and metabolism [11]. In recent years, the field of metabolomics has
41 gained traction due to technological advances [12] and has uncovered various
42 metabolites that are consistent predictors of T2D [13]. As many of these metabolic
43 biomarkers are modifiable by diet or other lifestyle factors, information on metabolic
44 risk factors may guide personalized interventions.

45

46 Previous studies on metabolic profiles and T2D risk were mostly conducted in
47 populations of predominantly European ancestry, and it remains unclear if these
48 findings can be generalized to different Asian ethnic groups. For example, individuals
49 of Asian origin tend to develop T2D at a lower body mass index (BMI) and a younger
50 age than those of European origin [7], and ethnic Indians are generally more insulin
51 resistant than ethnic Malays or Chinese [14]. Although some metabolomics studies on
52 T2D incidence have been conducted in East Asian (e.g. Chinese) populations, data on
53 South East Asian (e.g. Malays) and South Asian (e.g. Indians) populations are limited
54 [13].

55

56 We therefore evaluated whether associations between biomarkers reflecting a variety
57 of biological pathways and diabetes incidence differed between Asian and European
58 ethnic groups. We quantified amino acids, an inflammatory marker, fatty acids,
59 lipoprotein and ketone bodies using nuclear magnetic resonance (NMR) metabolomic
60 analysis in two multi-ethnic cohorts in Singapore and three cohorts in Finland. NMR
61 metabolomics allows for highly reproducible identification and quantification of
62 compounds [15, 16]. We subsequently performed association analyses of these
63 metabolic measures with risk of T2D in three major Asian ethnic groups (Chinese,
64 Malay, and Indian) and the European population.

65

66 **Methods**

67 *Study Population*

68 The Asian participants included in this study were from two population-based cohorts
69 in Singapore that included ethnic Indians, Malays and Chinese: the Multiethnic
70 Cohort (MEC) [17] study and the Singapore Epidemiology of Eye Diseases (SEED)
71 cohort study [18, 19]. The European participants in our study were from three Finnish
72 prospective population-based cohorts (FINRISK 2002, FINRISK 2012 and Health
73 2000) [20, 21]. All studies included questionnaires about socio-demographic
74 characteristics and medical history, technician-measurement of anthropometric
75 measures and blood pressure, and collection of blood samples. Details of the
76 individual cohorts are provided in the **Supplemental Text**. Informed consent was
77 obtained from all participants and ethical approvals were obtained from the respective
78 ethics review boards.

79

80 For all cohorts, we excluded participants with diabetes, cardiovascular diseases or
81 cancer at baseline. From the MEC cohort of 9180 participants, we identified 694
82 incident diabetes cases using the following criteria: (a) fasting plasma glucose ≥ 7.0
83 mmol/L or HbA1c ≥ 6.5 % (47.5 mmol/mol) based on the American Diabetes
84 Association [22] or self-reported physician-diagnosed diabetes at follow-up, or (b)
85 record linkage with a national database of medical diagnoses as part of public
86 hospital, polyclinic, and subsidized GP visits). Using risk-set sampling, we selected
87 1315 controls matched for age (± 5 years), sex, date of health screening (± 2 years),
88 and ethnicity from cohort participants who were alive, and did not have diabetes at the
89 time the index case occurred. We used 6-year revisit data from 4384 SEED cohort
90 participants among whom 391 developed diabetes during follow-up. Diabetes
91 ascertainment at baseline and the revisit was based on random glucose ≥ 11.1 mmol/L
92 or HbA1c ≥ 6.5 % (47.5 mmol/mol) [22], or a self-reported physician diagnosis. For
93 the European cohorts, we used data on 14588 participants from FINRISK 2002,
94 FINRISK 2012 and Health 2000, among whom 1055 developed diabetes during
95 follow-up. Diabetes ascertainment at baseline was based on the National Social
96 Insurance Institution Drug Purchase and Reimbursement Registries for purchases and
97 reimbursements of purchases of hypoglycemic drugs, and the National Hospital
98 Discharge Register for hospitalizations with diabetes as the diagnosis. Incident
99 diabetes cases were identified by linking the participants to the registers described
100 above with a unique personal identification code assigned to each Finnish citizen.
101 Participants with prevalent or incident gestational diabetes were excluded.

102

103 *Metabolic Biomarker Quantification and Quality Control*

104 Metabolic biomarkers were quantified from plasma (MEC, SEED Malays and
105 European cohorts) and serum (SEED Chinese and SEED Indians) samples at baseline
106 using a high-throughput ¹H-NMR metabolomics platform developed by Nightingale
107 Health Ltd. (Helsinki, Finland; [nightingalehealth.com/; biomarker quantification
108 version 2016](https://nightingalehealth.com/biomarker-quantification-version-2016)). Details of the procedure have been described previously [23, 24]. The
109 metabolic biomarkers quantified reflected several etiologically diverse pathways, such
110 as amino acids, fatty acids, ketone bodies, and gluconeogenesis-related
111 measurements. In addition, lipoprotein measures including total concentration, total
112 lipids, phospholipids, total cholesterol, cholesterol esters, free cholesterol and
113 triglycerides within 14 lipoprotein subclasses were measured. 9 MEC and 20 SEED
114 participants had >10% missing metabolic biomarker values and were excluded from
115 subsequent analyses. For participants with metabolic biomarker values lower than
116 detection level, we replaced values of 0 with a value equivalent to 0.9 multiplied by
117 the non-zero minimum value of that measurement. Finally, we standardized the
118 metabolic biomarker concentrations to z-scores, and all effect sizes were reported as
119 per standard deviation increment to enable comparison of metabolic biomarker
120 associations for measures with different units and concentration ranges. A total of 154
121 individual metabolic biomarkers were included in our analyses.

122

123 *Statistical analyses*

124 We first calculated Pearson's correlation coefficients for all 154 metabolic
125 biomarkers. Logistic regression was then used to assess associations between
126 circulating metabolic biomarkers with T2D. We did not use Cox regression because
127 most of the T2D cases were detected during revisit and the time-to-event data
128 therefore did not accurately reflect time from baseline to disease onset. For the

129 matched MEC case-control study, conditional logistic regression model was used. In
130 all studies, we adjusted for baseline age, sex, BMI, and fasting glucose (for MEC and
131 Health 2000) or glycated hemoglobin (HbA1c, for non-fasting SEED, FINRISK 2002
132 and 2012 cohorts). For MEC, age² was included in the conditional logistic model as
133 there was evidence of non-linearity in the relationship between age and T2D risk.
134 Logistic models were performed separately by study and ethnic group to account for
135 differences between populations. Inverse variance-weighted fixed-effect meta-
136 analysis was used to first pool ethnic-specific association statistics from the two
137 Singapore cohorts, and then to combine association results from three ethnic groups.
138 We also tested for heterogeneity using the Cochran Q heterogeneity. Bonferroni
139 correction was used to account for multiple testing of 154 metabolic biomarkers and P
140 <0.0003 ($0.05/154$) was considered statistically significant.

141

142 To test the joint effects of multiple metabolic biomarkers on risk of T2D, we first
143 performed the variable selection as described below and subsequently included the
144 selected metabolites in a multivariable logistic regression model. Due to the correlated
145 nature of the markers, we considered pairwise correlations between the metabolic
146 biomarkers from MEC (Supplement Table 1). For the set of T2D associated metabolic
147 biomarkers in the association analysis above that considered a metabolic biomarker
148 individually across Asian and European populations, we first sorted the metabolic
149 biomarkers by their strength of association. Starting with the most significantly
150 associated metabolic biomarker (index-associated metabolic biomarker), we
151 iteratively excluded other associated metabolic biomarkers that had correlations \geq
152 0.80 with the index-associated metabolic biomarker (correlation-pruning). The set of
153 remaining metabolic biomarkers thus had a Bonferroni-adjusted significant

154 association with T2D and pairwise correlations <0.80 . Finally, we performed stepwise
155 regression analysis with the criterion of P -value of 0.05 in a joint model that included
156 the selected biomarkers in the Asian and European cohorts. All statistical analyses
157 were conducted using R 3.3.2 (R Foundation for Statistical Computing, Vienna,
158 Austria).

159

160 **Results**

161 In the nested MEC case-control study, 694 incident T2D cases and 1315 matched
162 controls were included in this study during a mean follow-up of 6.9 y (standard
163 deviation SD: 2.4 y), and in the SEED cohort study, 391 incident T2D cases occurred
164 in 4384 participants during an average of 6.2 y (SD: 1.1 y). In the European cohorts,
165 1055 incident T2D cases occurred in 14,558 participants during an average of 11.3
166 years (SD: 5.0 y). The average age was 54.0 y (SD: 9.8 y) for the Asian participants
167 and 50.6 y (SD: 14.1 y) for the European participants, with similar representation of
168 males and females for all populations, and Chinese, Malays and Indians for the Asian
169 population (**Table 1**).

170

171 We observed high correlations among the branched-chain amino acids (BCAAs)
172 leucine, isoleucine and valine, and concentrations of n-6 polyunsaturated (n-6 PUFA)
173 fatty acids, PUFA, monounsaturated fatty acids (MUFA), saturated fatty acids and
174 linoleic acid (18:2n-6) (all $r>0.80$) (**Supplemental Tables 1 to 4**). In general, the lipid
175 components (total lipids, phospholipids, cholesterol esters, free cholesterol) with the
176 exception of triglycerides within a particular lipoprotein subclass were also highly
177 correlated. Overall, 59 of the 154 metabolic biomarkers were consistently associated
178 with a higher risk and 13 with a lower risk of T2D in both Asians and Europeans

179 ($P_{meta} < 0.0003$; Bonferroni-corrected; $P_{het} < 0.05$ for 12 metabolic biomarkers)
180 (**Table 2, Figure 1 and Supplemental Table 5**) after adjustment for age, sex, BMI
181 and either fasting glucose or HbA1c. For the population-specific meta-analysis, we
182 observed little heterogeneity in association across the three Asian ethnic groups ($P_{het} \geq$
183 0.05 for all 154 metabolic biomarkers) and across the three European cohorts ($P_{het} \geq$
184 0.05 for 144 of 154 metabolic biomarkers). Of the 29 metabolic biomarkers for which
185 we did observe evidence for heterogeneity between the Asian and European
186 populations, 23 were lipoprotein measures.

187

188 *Amino Acids and Inflammation*

189 Higher concentrations of BCAAs (leucine, isoleucine, and valine), aromatic amino
190 acids (phenylalanine and tyrosine), and alanine were significantly and consistently
191 associated with higher T2D risk in both Asians and Europeans (all $P_{het} > 0.05$). The
192 strongest association was observed for leucine (Asians: OR 1.50 per 1 SD increment,
193 95% CI 1.35 - 1.66; Europeans: OR 1.36, 95% CI 1.27 - 1.46). The inflammatory
194 marker glycoprotein acetyls (GlycA) was also directly associated with risk of T2D
195 (Asians: OR 1.41, 95% CI 1.28 - 1.55; Europeans: OR 1.34, 95% CI 1.25 - 1.43; P_{het}
196 = 0.37). GlycA remained directly associated with T2D risk after further adjustments
197 for CRP (data available only for MEC and the European cohorts, Asians: OR 1.94,
198 95% CI 1.63 - 2.31; Europeans: OR 1.34, 95% CI 1.25 - 1.44).

199

200 *Fatty Acids*

201 Higher total concentrations of fatty acids were significantly associated with higher
202 T2D risk. Among the different types of fatty acids, a higher proportion of MUFA was
203 consistently associated with a higher T2D risk (Asians: OR 1.43, 95% CI 1.30 - 1.57;

204 Europeans: OR 1.38, 95% CI 1.27 - 1.51), and a higher proportion of n-6 PUFA with
205 a lower risk (Asians: OR 0.70, 95% CI 0.64 - 0.77; Europeans: OR 0.70, 95% CI 0.65
206 - 0.75). The proportion of saturated fat (SFA) was directly associated with T2D risk,
207 but this was not statistically significant after Bonferroni correction in Asians (Asians:
208 OR 1.15, 95% CI: 1.05 - 1.25; Europeans: OR 1.21, 95% CI 1.13 - 1.29). n-3 PUFAs
209 were not significantly associated with risk of T2D in any ethnic group. There was no
210 evidence of heterogeneity for associations of fatty acids with T2D between the Asian
211 and European populations (all $P_{\text{het}} > 0.05$).

212

213 *Lipoprotein Measures*

214 We evaluated lipoprotein particle sizes, apolipoproteins and various lipoprotein
215 measures including total concentrations, total lipids, phospholipids, total cholesterol,
216 cholesterol esters, free cholesterol and triglycerides for 14 lipoprotein subclasses, in
217 relation to T2D (**Figure 1** and **Supplemental Table 5**).

218

219 Higher levels of apolipoprotein B were associated with higher T2D risk in both
220 Asians (OR 1.24, 95% CI 1.13 - 1.35) and Europeans (OR 1.22, 95% CI 1.13 - 1.30;
221 $P_{\text{het}} = 0.45$). Larger VLDL particle size was among the metabolic biomarkers with the
222 strongest direct associations with T2D risk (Asians: OR 1.44, 95% CI 1.31 - 1.59;
223 Europeans: OR 1.46, 95% CI 1.36 - 1.57; $P_{\text{het}} = 0.83$). Larger LDL particle sizes were
224 inversely associated with incident T2D risk in Europeans (OR 0.82, 95% CI 0.76 -
225 0.89), but not in Asians (Asians: OR 0.98, 95% CI 0.89 - 1.07; $P_{\text{het}} = 0.01$). Larger
226 HDL particle sizes were also more strongly inversely associated with T2D risk in
227 Europeans (OR 0.63, 95% CI 0.58 - 0.69) as compared with Asians (OR 0.77, 95% CI
228 0.69 - 0.86; $P_{\text{het}} = 0.01$).

229

230 The concentration of cholesterol in very low-density lipoprotein (VLDL) particles
231 was generally associated with higher risk of T2D in both Asians and Europeans (all
232 $P_{\text{het}} > 0.05$), with the strongest association observed for cholesterol in large VLDL
233 particles (Asians: OR 1.41, 95% CI 1.29 - 1.53; Europeans: OR 1.29, 95% CI 1.22 -
234 1.37; $P_{\text{het}} = 0.10$). Because the lipid components (total lipids, phospholipids,
235 cholesterol esters, free cholesterol, triglycerides) in VLDL particles were highly
236 correlated (**Supplemental Tables 1 to 4**), particularly in extremely large VLDL, very
237 large VLDL, large VLDL and medium VLDL (Pearson's $r > 0.85$), these lipid
238 components were similarly associated with T2D risk as VLDL cholesterol.

239

240 Total high-density lipoprotein (HDL) cholesterol was inversely associated with T2D
241 risk in Asians (OR 0.85, 95% CI 0.76 - 0.94) and Europeans (OR 0.76, 95% CI 0.69 -
242 0.82; $P_{\text{het}} = 0.09$), although this did not reach Bonferroni-corrected significance in
243 Asians. These inverse associations appeared to be driven by cholesterol in very large
244 and large HDL particles, which were stronger in Europeans than in Asians (very large
245 HDL: $P_{\text{het}} = 0.02$; large HDL: $P_{\text{het}} = 0.04$). Other lipid components of HDL (total lipids,
246 phospholipids, cholesterol esters, free cholesterol) with the exception of triglycerides
247 were similarly associated with T2D risk as the cholesterol component of HDL. There
248 were no significant associations between intermediate-density lipoprotein (IDL)
249 cholesterol and low-density lipoprotein (LDL) cholesterol concentrations and T2D
250 risk.

251

252 Elevated concentrations of total triglycerides were significantly associated with a
253 higher risk of T2D in Asians (OR 1.43, 95% 1.31 - 1.57) and Europeans (OR 1.32,

254 95% CI 1.25 - 1.40; $P_{\text{het}} = 0.14$). Results were similar when we analyzed triglycerides
255 in subclasses of VLDL, LDL, and HDL, with the exception of triglycerides in large
256 HDL.

257

258 *Other Metabolic Biomarkers*

259 We also evaluated ketone bodies, glycerides, phospholipids, and metabolites related
260 to glycolysis and fluid balance (**Table 2**). Higher phosphoglyceride concentrations
261 were associated with T2D risk but this remained significant after Bonferroni
262 correction only in Asians (OR 1.18, 95% CI 1.08 - 1.30) and not in Europeans (OR
263 1.08, 95% CI 1.01, 1.16; $P_{\text{het}} = 0.14$). Similarly, higher albumin concentrations were
264 significantly associated with a higher risk of T2D in Asians (OR 1.23, 95% CI: 1.12 -
265 1.35), but not Europeans (OR 1.12, 95% CI 0.97 - 1.28; $P_{\text{het}} = 0.25$).

266

267 *Joint Effects of Metabolic Biomarkers on Risk of T2D*

268 Using the correlation-pruning method, 12 metabolic biomarkers in MEC were
269 significantly associated with T2D with pairwise correlations with all other biomarkers
270 <0.80 . These were isoleucine, valine, phenylalanine, tyrosine, alanine, GlycA,
271 unsaturation index, proportion of n-6 PUFA, proportion of MUFA, VLDL size, small
272 VLDL particle concentration, and very large HDL phospholipids. Stepwise regression
273 selected a multivariable model that simultaneously included isoleucine, GlycA,
274 unsaturation index, and very large HDL phospholipids (**Supplemental Table 6**).
275 Higher levels of isoleucine (Asians: OR 1.25, 95% CI 1.10 - 1.42; Europeans: 1.18,
276 95% CI 1.06 - 1.31) and GlycA (Asians: OR 1.17, 95% CI 1.03 - 1.33; Europeans:
277 OR 1.06, 95% CI 0.95 - 1.18) were associated with higher T2D risk, and very large
278 HDL phospholipids with lower T2D risk (Asians: OR 0.88, 95% CI 0.77 - 0.99;

279 Europeans: OR 0.70, 95% CI 0.62 - 0.78). There was no independent significant
280 association between unsaturation index and T2D risk. We observed evidence of
281 heterogeneity between the Asian and European populations only for very large HDL
282 phospholipids ($P_{\text{het}} = 0.01$).

283

284 **Discussion**

285 We quantified 154 metabolic biomarkers using NMR technology in plasma and serum
286 samples from five prospective cohort studies representing three major ethnic groups
287 in Asia (Chinese, Malay, and Indian) and a European population. While there have
288 been previous metabolomics studies in Asians and individuals of European descent,
289 these were mostly conducted separately in ethnically homogenous populations with
290 cross-sectional study design, different metabolomics platforms or statistical methods
291 that did not facilitate direct comparison of results [13, 25]. Here, we report that
292 branched-chain amino acids, aromatic amino acids, alanine, the inflammatory marker
293 GlycA, total fatty acids, the proportion of MUFA, apolipoprotein B, larger VLDL
294 particle sizes and triglycerides were consistently associated with a higher T2D risk in
295 Asians and Europeans. Furthermore, the proportion of n-6 PUFA and larger HDL
296 particle sizes were consistently associated with a lower T2D risk in Asians and
297 Europeans. Overall, associations were consistent across the Asian ethnic groups, and
298 largely consistent for the Asian and European populations.

299

300 Our finding that higher concentrations of BCAAs (leucine, isoleucine and valine)
301 were associated with a higher risk of T2D is consistent with the results of previous
302 prospective studies [13, 23, 25-30]. Results from Mendelian randomization studies
303 suggest that BCAA metabolites play a causal role in the pathogenesis of T2D [30]. In

304 line with our results, the aromatic amino acids phenylalanine and tyrosine were
305 directly associated with T2D risk in a meta-analysis of prospective studies [13], and
306 alanine was directly associated with T2D risk in a Japanese cohort [27]. Elevated
307 concentrations of aromatic amino acids and alanine have been hypothesized to induce
308 insulin resistance, possibly by inhibition of glucose transport and phosphorylation in
309 skeletal muscle [13, 31, 32].

310

311 A higher concentration of the inflammatory marker GlycA was associated with a
312 higher risk of T2D in our study, which is compatible with results from the Dutch
313 PREVEND study and the U.S. Women's Health Study [33, 34]. GlycA is a composite
314 NMR measure that arises from the *N*-acetyl methyl group protons of oligosaccharide
315 moieties of acute-phase proteins [35], proteins whose concentrations change in
316 response to inflammation. As opposed to CRP, which is characterized by multi-fold
317 elevation in acute state, GlycA levels fluctuate less on short-term bases and may
318 therefore capture different aspects of the inflammatory response [36], a hypothesis
319 supported by our results and results of the PREVEND study as GlycA remains
320 directly associated with T2D risk after adjusting for CRP [33]. However, in the
321 Women's Health Study, the association between GlycA and incident T2D was
322 significantly attenuated after adjusting for CRP [34]. It is plausible that low-grade
323 inflammation is involved in the pathogenesis of T2D through insulin resistance and
324 beta-cell dysfunction [37, 38].

325

326 Our report of a direct association between circulating MUFA and T2D risk is
327 consistent with a previous finding in a Finnish cohort [39], but not with the
328 Atherosclerosis Risk in Communities (ARIC) study [40]. Because MUFA can be

329 synthesized endogenously from SFA [41], MUFAs concentrations may reflect SFA
330 intake. We also observed a direct association between circulating SFA and T2D risk
331 although this was not significant in Asians. In the ARIC study [40] and a Finnish
332 cohort [39], a higher proportion of SFA was also associated with higher T2D risk. It
333 has been hypothesized that high SFA concentrations promote insulin resistance and
334 are lipotoxic to beta-cells [42, 43]. Our study further showed that higher proportions
335 of n-6 PUFAs were associated with a lower risk of T2D, concordant with a previous
336 meta-analysis of prospective cohort studies [44]. The association may be partly
337 mediated by increasing insulin sensitivity through increasing cellular membrane
338 fluidity [45, 46], particularly of skeletal muscle cells and hepatocytes [45, 46], and by
339 acting as ligands for peroxisome proliferator-activated receptor gamma [47, 48].
340 These hypotheses are supported by a meta-analysis of randomized feeding trials that
341 showed improvements in glucose-insulin homeostasis for dietary PUFA compared to
342 SFA or MUFA [49]. In a recent Mendelian randomization study, genetic
343 predisposition to higher levels of linoleic acid was associated with a lower risk of
344 T2D [50], supporting a causal effect of linoleic acid on T2D. The lack of association
345 between the relative fraction of n-3 PUFA and T2D risk is consistent with a previous
346 meta-analysis of prospective studies [51].
347
348 We also identified several patterns in the lipoprotein profile that were consistently
349 associated with T2D risk across ethnic groups. Larger VLDL particles were directly
350 associated with T2D risk, similar to existing evidence from prospective studies [23,
351 52-54]. VLDL is mostly comprised of triglycerides, and larger particles carry more
352 triglycerides [54]. The causal relationship between circulating triglycerides and T2D
353 is still a matter of debate [55] and there was no consensus among studies on

354 genetically influenced triglyceride levels and T2D incidence [56, 57]. Our finding that
355 the concentration of larger HDL particles was inversely associated with T2D risk also
356 agrees with previous prospective studies in western populations [23, 52-54]. While
357 HDL lipid components (e.g. phospholipids, cholesterol esters, free cholesterol) in very
358 large and large HDL particles were associated with lower risk of T2D, they were not
359 associated with T2D risk in medium and small HDL particles. This suggests that the
360 inverse associations observed for HDL lipid components were driven by particle size
361 rather than lipid composition. Larger HDL particles have been hypothesized to be
362 more efficient in cholesterol efflux capacity than smaller HDL particles [58, 59]. HDL
363 particles may also have other anti-diabetic properties such as promoting insulin
364 secretion and glucose uptake in skeletal muscle cells [60].

365

366 Our study's strengths included the use of large population-based cohorts collected in
367 diverse populations with reasonable follow-up times that allowed us to have sufficient
368 statistical power to evaluate the associations separately in each ethnic group and for
369 heterogeneity between populations. However, we also acknowledge certain
370 limitations. First, a limitation of NMR technology compared to mass spectrometry is
371 its lower sensitivity, and we could not quantify metabolic biomarkers that were below
372 the detection limit of NMR. Second, participants of the SEED cohorts were not
373 required to fast and this may have affected levels of certain metabolic biomarkers
374 such as triglycerides and amino acids [61, 62]. However, this would have more likely
375 weakened than strengthened the observed associations. Third, different T2D case
376 ascertainment were used for the cohorts and this may have affected comparability of
377 the results. However, despite different methodologies in case ascertainment, we

378 obtained consistent results across the different cohorts. Finally, we cannot rule out
379 residual confounding due to unmeasured or imperfectly measured risk factors.
380
381 Our results may have implications in clinical practice, including the prevention and
382 treatment, and early detection and prognosis of T2D. The metabolic biomarkers
383 associated with T2D risk in our study are modifiable and may thus provide targets for
384 lifestyle and pharmacological interventions for prevention and treatment. For
385 example, replacing dietary SFA with PUFA has long been part of dietary
386 recommendation to reduce cardiovascular disease risk [63] and may also reduce T2D
387 risk by improving plasma fatty acid profiles. Similarly, dietary BCAAs and aromatic
388 amino acids are primarily from animal products, such as meat, and lower consumption
389 may reduce T2D risk partly by improving circulating amino acids [64–66] and insulin
390 sensitivity [67]. Furthermore, cholesteryl ester transfer protein inhibitors are a drug
391 class that is known to preferentially increase larger HDL particles [68, 69]. In a meta-
392 analysis of four randomized trials, these drugs significantly reduced T2D risk
393 although it is unclear if this effect is caused solely by changes in circulating HDL [68-
394 70]. Because these metabolic biomarkers reflect modifiable pathways, metabolic
395 profiling data could inform ‘precision medicine’ approaches that prioritize specific
396 preventive interventions for individuals at high risk of T2D. Various biomarkers such
397 as BCAAs and aromatic amino acids may be etiologically involved in insulin
398 resistance [31, 71], and the inclusion of these biomarkers to prediction models of T2D
399 improved area under curve (AUC) [72]. As the biological pathways involved in the
400 pathogenesis of T2D appear to be similar in Asians and Europeans, these
401 interventions and approaches for detection and prediction may be effective for both
402 populations.

403

404 Several physiological differences have been proposed to contribute to the higher
405 susceptibility to developing T2D in Asians than Europeans [7]. For example, greater
406 visceral adiposity and less lean body mass may contribute to the higher rates of T2D
407 in South Asians as compared with European ancestry populations [7, 73, 74]. The
408 generally consistent associations for metabolic biomarkers across diverse ethnic
409 groups in our study suggest that differences in the degree of metabolic disturbances in
410 the evaluated pathways rather than differences in the pathways involved contribute to
411 ethnic differences in risk of T2D. However, there may be exceptions for selected
412 biological pathways. For example, South Asians have been found to have smaller
413 mean HDL particle sizes as compared with European ancestry populations [75] and
414 this may contribute to the higher risk of T2D in South Asians through less efficient
415 reverse cholesterol transport and dyslipidemia [58]. Our observation of possibly
416 stronger inverse associations between HDL and T2D risk in Europeans than Asians,
417 particularly for very large HDL, is novel and warrants further studies.

418

419 We found consistent associations between metabolic signatures and risk of T2D in
420 prospective cohorts in Asia and Europe. Metabolic aberrations that spanned multiple
421 pathways, including amino acids, inflammation, fatty acids and lipoproteins were
422 similarly associated with T2D risk in major Asian ethnic groups and Europeans
423 despite environmental, lifestyle, and physiological differences. Our results suggest
424 that these are candidates for better prediction of T2D in different ethnic groups that
425 require further evaluation in prognostic studies. Moreover, these metabolic
426 biomarkers are modifiable and may be targets for preventive interventions across

427 different ethnic groups. Metabolic profiles may inform future personalized
428 interventions for the prevention of T2D in increasingly cosmopolitan populations.

429

430 **Acknowledgements**

431 All authors have no conflicts of interest.

432

433 CS, SN, TYW, C-YC, PJ, AL, MP, VS, EST, PW, RMvD and XS and conceived and
434 designed research. AC and PW conducted experiments. CS, SN, TYW, C-YC, PJ,
435 AL, MP, VS, EST, PW and RMvD contributed data. JYHS, YH, AC and XS analyzed
436 data. JYHS, RMvD and XS wrote the manuscript and had primary responsibility for
437 final content. All authors read and approved the manuscript.

438

439 The authors thank all investigators, staff members, and study participants for their
440 contributions to all the participating studies. The MEC is supported by grants from the
441 Singapore Ministry of Health, including National Medical Research Council Large
442 Collaborative Grant (MOH-000271-00), National University of Singapore and
443 National University Health System, Singapore. Metabolic profiling for MEC was
444 supported by NUHS Summit Research Program (Metabolic Diseases) and performed
445 by Nightingale Health Ltd. The SEED cohorts are supported by the National Medical
446 Research Council (NMRC), Singapore (grants 0796/2003, 1176/2008, 1149/2008,
447 STaR/0003/2008, 1249/2010, CG/SERI/2010, CIRG/1371/2013, CIRG/1417/2015,
448 CIRG/1488/2018 and OFLCG/004a/2018), and Biomedical Research Council
449 (BMRC), Singapore (08/1/35/19/550 and 09/1/35/19/616). VS was supported by the
450 Finnish Foundation for Cardiovascular Research. JYHS was supported by the

451 Singapore Ministry of Health's National Medical Research Council Large

452 Collaborative Grant (MOH-000271-00).

453

454 **Disclosures**

455 A. Cichońska and P. Wuertz are employees and shareholders of Nightingale

456 Health Ltd., a company offering NMR-based biomarker profiling.

457 B. VS has received honoraria for consulting for Novo Nordisk and Sanofi. He

458 also has ongoing research collaboration with Bayer Ltd (All unrelated to the

459 present study).

460

461 **Data availability**

462 Data described in the manuscript, code book and analytic code will be made available

463 upon request pending application and approval.

References

1. Nanditha, A., et al., *Diabetes in Asia and the Pacific: Implications for the Global Epidemic*. Diabetes Care, 2016. **39**(3): p. 472-485.
2. Khan, M.A.B., et al., *Epidemiology of Type 2 Diabetes - Global Burden of Disease and Forecasted Trends*. Journal of Epidemiology and Global Health, 2020. **10**(1): p. 107-111.
3. Uusitupa, M., et al., *Prevention of Type 2 Diabetes by Lifestyle Changes: A Systematic Review and Meta-Analysis*. Nutrients, 2019. **11**(11).
4. Gillies, C.L., et al., *Pharmacological and lifestyle interventions to prevent or delay type 2 diabetes in people with impaired glucose tolerance: systematic review and meta-analysis*. British Medical Journal, 2007. **334**(7588): p. 299-302B.
5. Sheng, Z., et al., *Effects of Lifestyle Modification and Anti-diabetic Medicine on Prediabetes Progress: A Systematic Review and Meta-Analysis*. Frontiers in Endocrinology, 2019. **10**.
6. Kodama, K., et al., *Ethnic Differences in the Relationship Between Insulin Sensitivity and Insulin Response A systematic review and meta-analysis*. Diabetes Care, 2013. **36**(6): p. 1789-1796.
7. Chan, J.C.N., et al., *Diabetes in Asia Epidemiology, Risk Factors, and Pathophysiology*. Jama-Journal of the American Medical Association, 2009. **301**(20): p. 2129-2140.
8. Philipson, L.H., *Harnessing heterogeneity in type 2 diabetes mellitus*. Nature Reviews Endocrinology, 2020. **16**(2): p. 79-80.

9. Prasad, R.B. and L. Groop, *Precision medicine in type 2 diabetes*. Journal of Internal Medicine, 2019. **285**(1): p. 40-48.
10. Palmnäs, M., et al., *Perspective: Metabotyping-A Potential Personalized Nutrition Strategy for Precision Prevention of Cardiometabolic Disease*. Adv Nutr, 2020. **11**(3): p. 524-532.
11. Wishart, D.S., *Emerging applications of metabolomics in drug discovery and precision medicine*. Nature Reviews Drug Discovery, 2016. **15**(7): p. 473-484.
12. Putri, S.P., et al., *Current metabolomics: Technological advances*. Journal of Bioscience and Bioengineering, 2013. **116**(1): p. 9-16.
13. Guasch-Ferre, M., et al., *Metabolomics in Prediabetes and Diabetes: A Systematic Review and Meta-analysis*. Diabetes Care, 2016. **39**(5): p. 833-846.
14. Gao, H., et al., *Can body fat distribution, adiponectin levels and inflammation explain differences in insulin resistance between ethnic Chinese, Malays and Asian Indians?* International Journal of Obesity, 2012. **36**(8): p. 1086-1093.
15. Markley, J.L., et al., *The future of NMR-based metabolomics*. Current Opinion in Biotechnology, 2017. **43**: p. 34-40.
16. Marshall, D.D. and R. Powers, *Beyond the paradigm: Combining mass spectrometry and nuclear magnetic resonance for metabolomics*. Progress in Nuclear Magnetic Resonance Spectroscopy, 2017. **100**: p. 1-16.
17. Tan, K.H.X., et al., *Cohort Profile: The Singapore Multi-Ethnic Cohort (MEC) study*. Int J Epidemiol, 2018.
18. Lavanya, R., et al., *Methodology of the Singapore Indian Chinese Cohort (SICC) Eye Study: Quantifying ethnic variations in the epidemiology of eye diseases in Asians*. Ophthalmic Epidemiology, 2009. **16**(6): p. 325-336.

19. Rosman, M., et al., *Singapore Malay Eye Study: rationale and methodology of 6-year follow-up study (SiMES-2)*. *Clinical and Experimental Ophthalmology*, 2012. **40**(6): p. 557-568.
20. Borodulin, K., et al., *Cohort Profile: The National FINRISK Study*. *International Journal of Epidemiology*, 2018. **47**(3): p. 696-+.
21. Pirkola, S.P., et al., *DSM-IV mood-, anxiety- and alcohol use disorders and their comorbidity in the Finnish general population - Results from the Health 2000 Study*. *Social Psychiatry and Psychiatric Epidemiology*, 2005. **40**(1): p. 1-10.
22. *2. Classification and Diagnosis of Diabetes: Standards of Medical Care in Diabetes-2020*. *Diabetes Care*, 2020. **43**(Suppl 1): p. S14-s31.
23. Ahola-Olli, A.V., et al., *Circulating metabolites and the risk of type 2 diabetes: a prospective study of 11,896 young adults from four Finnish cohorts*. *Diabetologia*, 2019. **62**(12): p. 2298-2309.
24. Soininen, P., et al., *Quantitative Serum Nuclear Magnetic Resonance Metabolomics in Cardiovascular Epidemiology and Genetics*. *Circulation-Cardiovascular Genetics*, 2015. **8**(1): p. 192-206.
25. Tillin, T., et al., *Diabetes risk and amino acid profiles: cross-sectional and prospective analyses of ethnicity, amino acids and diabetes in a South Asian and European cohort from the SABRE (Southall And Brent REvisited) Study*. *Diabetologia*, 2015. **58**(5): p. 968-979.
26. Flores-Guerrero, J.L., et al., *Plasma Branched-Chain Amino Acids and Risk of Incident Type 2 Diabetes: Results from the PREVEND Prospective Cohort Study*. *Journal of Clinical Medicine*, 2018. **7**(12).

27. Chen, S.M., et al., *Serum amino acid profiles and risk of type 2 diabetes among Japanese adults in the Hitachi Health Study*. Scientific Reports, 2019. **9**.
28. Satheesh, G., S. Ramachandran, and A. Jaleel, *Metabolomics-Based Prospective Studies and Prediction of Type 2 Diabetes Mellitus Risks*. Metabolic Syndrome and Related Disorders, 2020. **18**(1): p. 1-9.
29. Lu, Y.H., et al., *Metabolic signatures and risk of type 2 diabetes in a Chinese population: an untargeted metabolomics study using both LC-MS and GC-MS*. Diabetologia, 2016. **59**(11): p. 2349-2359.
30. Lotta, L.A., et al., *Genetic Predisposition to an Impaired Metabolism of the Branched-Chain Amino Acids and Risk of Type 2 Diabetes: A Mendelian Randomisation Analysis*. Plos Medicine, 2016. **13**(11).
31. Wurtz, P., et al., *Branched-Chain and Aromatic Amino Acids Are Predictors of Insulin Resistance in Young Adults*. Diabetes Care, 2013. **36**(3): p. 648-655.
32. Krebs, M., et al., *Mechanism of amino acid-induced skeletal muscle insulin resistance in humans*. Diabetes, 2002. **51**(3): p. 599-605.
33. Connelly, M.A., et al., *GlycA, a marker of acute phase glycoproteins, and the risk of incident type 2 diabetes mellitus: PREVEND study*. Clinica Chimica Acta, 2016. **452**: p. 10-17.
34. Akinkuolie, A.O., et al., *Novel protein glycan side-chain biomarker and risk of incident type 2 diabetes mellitus*. Arterioscler Thromb Vasc Biol, 2015. **35**(6): p. 1544-50.
35. Connelly, M.A., et al., *GlycA, a novel biomarker of systemic inflammation and cardiovascular disease risk*. Journal of Translational Medicine, 2017. **15**.

36. Ritchie, S.C., et al., *The Biomarker GlycA Is Associated with Chronic Inflammation and Predicts Long-Term Risk of Severe Infection*. Cell Systems, 2015. **1**(4): p. 293-301.
37. Hameed, I., et al., *Type 2 diabetes mellitus: From a metabolic disorder to an inflammatory condition*. World Journal of Diabetes, 2015. **6**(4): p. 598-612.
38. Jin, C.C., J. Henao-Mejia, and R.A. Flavell, *Innate Immune Receptors: Key Regulators of Metabolic Disease Progression*. Cell Metabolism, 2013. **17**(6): p. 873-882.
39. Mahendran, Y., et al., *Glycerol and Fatty Acids in Serum Predict the Development of Hyperglycemia and Type 2 Diabetes in Finnish Men*. Diabetes Care, 2013. **36**(11): p. 3732-3738.
40. Wang, L., et al., *Plasma fatty acid composition and incidence of diabetes in middle-aged adults: the Atherosclerosis Risk in Communities (ARIC) Study*. American Journal of Clinical Nutrition, 2003. **78**(1): p. 91-98.
41. Nakamura, M.T. and T.Y. Nara, *Structure, function, and dietary regulation of Delta 6, Delta 5, and Delta 9 desaturases*. Annual Review of Nutrition, 2004. **24**: p. 345-376.
42. Oh, Y.S., et al., *Fatty Acid-Induced Lipotoxicity in Pancreatic Beta-Cells During Development of Type 2 Diabetes*. Frontiers in Endocrinology, 2018. **9**.
43. Sobczak, A.I.S., C.A. Blindauer, and A.J. Stewart, *Changes in Plasma Free Fatty Acids Associated with Type-2 Diabetes*. Nutrients, 2019. **11**(9).
44. Wu, J.H.Y., et al., *Omega-6 fatty acid biomarkers and incident type 2 diabetes: pooled analysis of individual-level data for 39 740 adults from 20 prospective cohort studies*. Lancet Diabetes & Endocrinology, 2017. **5**(12): p. 965-974.

45. Kroger, J., et al., *Erythrocyte membrane fatty acid fluidity and risk of type 2 diabetes in the EPIC-Potsdam study*. Diabetologia, 2015. **58**(2): p. 282-289.
46. Weijers, R.N.M., *Lipid Composition of Cell Membranes and Its Relevance in Type 2 Diabetes Mellitus*. Current Diabetes Reviews, 2012. **8**(5): p. 390-400.
47. Lai, M.C., T.H. Teng, and C. Yang, *The Natural PPAR Agonist Linoleic Acid Stimulated Insulin Release in the Rat Pancreas*. Journal of Veterinary Medical Science, 2013. **75**(11): p. 1449-1454.
48. Echeverria, F., et al., *Long-chain polyunsaturated fatty acids regulation of PPARs, signaling: Relationship to tissue development and aging*. Prostaglandins Leukotrienes and Essential Fatty Acids, 2016. **114**: p. 28-34.
49. Imamura, F., et al., *Effects of Saturated Fat, Polyunsaturated Fat, Monounsaturated Fat, and Carbohydrate on Glucose-Insulin Homeostasis: A Systematic Review and Meta-analysis of Randomised Controlled Feeding Trials*. Plos Medicine, 2016. **13**(7).
50. Yuan, S. and S.C. Larsson, *Association of genetic variants related to plasma fatty acids with type 2 diabetes mellitus and glycaemic traits: a Mendelian randomisation study*. Diabetologia, 2020. **63**(1): p. 116-123.
51. Wu, J.H.Y., et al., *Omega-3 fatty acids and incident type 2 diabetes: a systematic review and meta-analysis*. British Journal of Nutrition, 2012. **107**: p. S214-S227.
52. Mackey, R.H., et al., *Lipoprotein Particles and Incident Type 2 Diabetes in the Multi-Ethnic Study of Atherosclerosis*. Diabetes Care, 2015. **38**(4): p. 628-636.

53. Hodge, A.M., et al., *NMR-determined lipoprotein subclass profile predicts type 2 diabetes*. Diabetes Research and Clinical Practice, 2009. **83**(1): p. 132-139.
54. Mora, S., et al., *Lipoprotein Particle Size and Concentration by Nuclear Magnetic Resonance and Incident Type 2 Diabetes in Women*. Diabetes, 2010. **59**(5): p. 1153-1160.
55. Hözl, B., et al., *Hypertriglyceridemia and insulin resistance*. J Intern Med, 1998. **243**(1): p. 79-82.
56. De Silva, N.M., et al., *Mendelian randomization studies do not support a role for raised circulating triglyceride levels influencing type 2 diabetes, glucose levels, or insulin resistance*. Diabetes, 2011. **60**(3): p. 1008-18.
57. Qi, Q.B., et al., *Genetic Predisposition to Dyslipidemia and Type 2 Diabetes Risk in Two Prospective Cohorts*. Diabetes, 2012. **61**(3): p. 745-752.
58. Khera, A.V., et al., *Cholesterol Efflux Capacity, High-Density Lipoprotein Particle Number, and Incident Cardiovascular Events: An Analysis From the JUPITER Trial (Justification for the Use of Statins in Prevention: An Intervention Trial Evaluating Rosuvastatin)*. Circulation, 2017. **135**(25): p. 2494-2504.
59. Rysz, J., et al., *The Role and Function of HDL in Patients with Chronic Kidney Disease and the Risk of Cardiovascular Disease*. International Journal of Molecular Sciences, 2020. **21**(2).
60. Drew, B.G., et al., *High-Density Lipoprotein Modulates Glucose Metabolism in Patients With Type 2 Diabetes Mellitus*. Circulation, 2009. **119**(15): p. 2103-U134.

61. Jackson, K.G., S.D. Poppitt, and A.M. Minihane, *Postprandial lipemia and cardiovascular disease risk: Interrelationships between dietary, physiological and genetic determinants*. *Atherosclerosis*, 2012. **220**(1): p. 22-33.
62. Ottosson, F., et al., *POSTPRANDIAL LEVELS OF BRANCH CHAINED AND AROMATIC AMINO ACIDS ASSOCIATED WITH FASTING GLYCAEMIA*. *Journal of Hypertension*, 2016. **34**: p. E145-E145.
63. Sacks, F.M., et al., *Dietary Fats and Cardiovascular Disease A Presidential Advisory From the American Heart Association*. *Circulation*, 2017. **136**(3): p. E1-+.
64. Isanejad, M., et al., *Branched-chain amino acid, meat intake and risk of type 2 diabetes in the Women's Health Initiative*. *British Journal of Nutrition*, 2017. **117**(11): p. 1523-1530.
65. Elshorbagy, A., et al., *Amino acid changes during transition to a vegan diet supplemented with fish in healthy humans*. *European Journal of Nutrition*, 2017. **56**(5): p. 1953-1962.
66. Gunther, S.H., et al., *Diet, Physical Activity and Adiposity as Determinants of Circulating Amino Acid Levels in a Multiethnic Asian Population*. *Nutrients*, 2020. **12**(9).
67. Karusheva, Y., et al., *Short-term dietary reduction of branched-chain amino acids reduces meal-induced insulin secretion and modifies microbiome composition in type 2 diabetes: a randomized controlled crossover trial*. *The American Journal of Clinical Nutrition*, 2019. **110**(5): p. 1098-1107.
68. Krauss, R.M., et al., *Changes in lipoprotein subfraction concentration and composition in healthy individuals treated with the CETP inhibitor anacetrapib*. *Journal of Lipid Research*, 2012. **53**(3): p. 540-547.

69. Kontush, A., *HDL particle number and size as predictors of cardiovascular disease*. *Frontiers in Pharmacology*, 2015. **6**.
70. Masson, W., et al., *Therapy with cholesteryl ester transfer protein (CETP) inhibitors and diabetes risk*. *Diabetes & Metabolism*, 2018. **44**(6): p. 508-513.
71. Batch, B.C., et al., *Branched chain amino acids are novel biomarkers for discrimination of metabolic wellness*. *Metabolism*, 2013. **62**(7): p. 961-9.
72. Gunther, S.H., et al., *Serum acylcarnitines and amino acids and risk of type 2 diabetes in a multiethnic Asian population*. *BMJ Open Diabetes Res Care*, 2020. **8**(1).
73. Rush, E.C., I. Freitas, and L.D. Plank, *Body size, body composition and fat distribution: comparative analysis of European, Maori, Pacific Island and Asian Indian adults*. *Br J Nutr*, 2009. **102**(4): p. 632-41.
74. Narayan, K.M.V. and A.M. Kanaya, *Why are South Asians prone to type 2 diabetes? A hypothesis based on underexplored pathways*. *Diabetologia*, 2020. **63**(6): p. 1103-1109.
75. Bilen, O., A. Kamal, and S.S. Virani, *Lipoprotein abnormalities in South Asians and its association with cardiovascular disease: Current state and future directions*. *World Journal of Cardiology*, 2016. **8**(3): p. 247-257.

Legends for figures

Figure 1. Associations between baseline circulating lipoprotein measures and risk of incident type 2 diabetes. Values are ORs (95% CIs) per 1 SD increment in metabolic biomarkers levels. The results for Asian participants (n=6393) were meta-analysed using data from Chinese (n=2676), Malay (n=1872) and Indian (n=1845) participants of the MEC and the SEED cohorts which consist of the Singapore Chinese Eye Study, Singapore Malay Eye Study and the Singapore Indian Eye Study. Results for the European participants (n=14558) were meta-analysed from 3 prospective Finnish cohorts (FINRISK 2002, FINRISK 2012 and Health 2000). We adjusted or matched for age, age² (only for MEC), sex, BMI and fasting glucose (MEC and Health 2000) or HbA1c (SEED cohorts, FINRISK 2002 and FINRISK 2012). We accounted for multiple testing using Bonferroni correction and *P*-values < 0.0003 were considered statistically significant. Abbreviations: ApoA1, apolipoprotein A1, ApoB, apolipoprotein B, HbA1c, glycated hemoglobin A1c, HDL, high-density lipoprotein, IDL, intermediate-density lipoprotein, LDL, low-density lipoprotein, MEC, Multiethnic Cohort, SEED, Singapore Epidemiology of Eye Diseases, VLDL, very low-density lipoprotein

Table 1. Baseline characteristics of participants of the cohorts included in the study¹

Characteristic	MEC			SEED ²			European cohorts		
	Chinese	Malay	Indian	Chinese	Malay	Indian	FINRISK 2002	FINRISK 2012	Health 2000
No. cases / No. controls	256/499	216/411	222/405	96/1825	132/1113	163/1055	350/3904	78/4475	627/6179
Follow-up duration (y)	7.4 ± 2.5	6.7 ± 2.5	6.6 ± 2.3	5.8 ± 0.9	7.1 ± 0.9	6.0 ± 0.9	13.8 ± 0.1	3.8 ± 0.1	15.1 ± 0.1
Age at interview (y)	53.6 ± 9.5	49.1 ± 9.9	47.8 ± 10.4	57 ± 8.6	54.8 ± 10	54.4 ± 8.4	48.5 ± 13.7	48.8 ± 13.8	53.2 ± 14.2
Male [n (%)]	356 (47.1)	234 (37.3)	257 (41)	889 (46.3)	563 (45.2)	568 (46.6)	1794 (45.9)	2088 (46.7)	2748 (44.5)
Education level ³									
Low	243 (32.2)	208 (33.2)	199 (31.8)	905 (47.1)	773 (62.2)	588 (48.4)	-	-	-
Intermediate	415 (55)	404 (64.5)	356 (56.9)	818 (42.6)	455 (36.6)	478 (39.3)	-	-	-
High	97 (12.8)	14 (2.2)	71 (11.3)	198 (10.3)	15 (1.2)	149 (12.3)	-	-	-
Body mass index (kg/m ²)	23.8 ± 3.7	26.9 ± 5	26.7 ± 4.9	23.4 ± 3.5	26 ± 4.7	25.7 ± 4.2	26.6 ± 4.5	26.6 ± 4.6	26.8 ± 4.6
Fasting glucose (mmol/L)	4.9 ± 0.6	5 ± 0.6	5.1 ± 0.6	-	-	-	-	-	5.4 ± 0.8
HbA1c (%) ⁴	5.6 ± 0.4	5.6 ± 0.4	5.8 ± 0.4	5.8 ± 0.3	5.7 ± 0.4	5.7 ± 0.4	5.4 ± 0.4	5.2 ± 0.3	-
Total cholesterol (mmol/L)	5.3 ± 0.9	5.6 ± 1	5.3 ± 0.9	5.6 ± 1	5.7 ± 1.1	5.5 ± 1	5.6 ± 1.1	5.4 ± 1.0	6.0 ± 1.1
HDL cholesterol (mmol/L)	1.4 ± 0.3	1.3 ± 0.3	1.1 ± 0.3	1.4 ± 0.4	1.4 ± 0.3	1.1 ± 0.3	1.5 ± 0.4	1.5 ± 0.4	1.4 ± 0.4
LDL cholesterol (mmol/L)	3.4 ± 0.8	3.6 ± 0.9	3.5 ± 0.8	3.4 ± 0.9	3.6 ± 1	3.6 ± 0.8	3.4 ± 0.9	3.3 ± 0.9	3.8 ± 1.1

Triglycerides (mmol/L)	1.2 (0.9,1.7)	1.2 (0.9,1.7)	1.3 (0.9,1.8)	1.4 (1.0,2.1)	1.3 (0.7,2.1)	1.6 (1.1,2.3)	1.1 (0.8, 1.6)	1.1 (0.8, 1.6)	1.3 (1.0, 1.8)
DBP (mmHg)	78.7 ± 11.3	76.4 ± 11.7	74.5 ± 11.5	77.6 ± 9.9	79.2 ± 11.0	77.9 ± 10.1	78.7 ± 11.4	81.3 ± 11.1	82.0 ± 11.0
SBP (mmHg)	134.2 ± 20.6	131.9 ± 20	125.3 ± 21.4	133.4 ± 18.4	141 ± 22.3	130.9 ± 18.7	135.0 ± 20.2	132.7 ± 18.6	134.2 ± 20.7

¹ Mean ± SD; median (Q1, Q3)

² SEED cohorts consist of a collection of three cohorts: Singapore Chinese Eye Study, Singapore Malay Eye Study and the Singapore Indian Eye Study. Participants of the SEED cohorts were not required to fast. LDL cholesterol was measured in the Singapore Chinese Eye Study and Singapore Indian Eye Study, and calculated in the Singapore Malay Eye Study.

³ We classified education level as follows: low – none, Primary or equivalent, intermediate – Secondary, diploma, Junior College, high school or equivalent, and high – college degree and above. The data for European cohorts could not be accessed.

⁴ Only a subset of participants in MEC (N = 598, 531, 516, for Chinese, Malay, and Indian) had HbA1c measurements. To convert HbA1c from % to mmol/mol, first multiply HbA1c (%) by 10.93 and then subtract 23.50.

Abbreviations: DBP, diastolic blood pressure, HbA1c, glycated hemoglobin A1c, HDL, high-density lipoprotein, LDL, low-density lipoprotein, MEC, Multiethnic Cohort, SEED, SBP, systolic blood pressure, Singapore Epidemiology of Eye Diseases, Q1, quantile 1, Q3, quantile 3

Table 2. Associations between non-lipoprotein metabolic biomarkers and type 2 diabetes¹

Metabolite	Chinese	Malay	Indian	Meta-analysis of Asians			Meta-analysis of Europeans			P-het (Asians and Europeans)
	OR (95% CI)	OR (95% CI)	OR (95% CI)	OR (95% CI)	P-value	P-het	OR (95% CI)	P-value	P-het	
Branched-chain amino acids										
Leucine	1.68 (1.41 - 2.00)	1.44 (1.19 - 1.73)	1.38 (1.16 - 1.64)	1.50 (1.35 - 1.66)	<0.0003	0.26	1.36 (1.27 - 1.46)	<0.0003	0.55	0.14
Isoleucine	1.68 (1.42 - 1.98)	1.43 (1.19 - 1.72)	1.33 (1.12 - 1.58)	1.48 (1.34 - 1.63)	<0.0003	0.15	1.36 (1.27 - 1.45)	<0.0003	0.76	0.17
Valine	1.54 (1.30 - 1.83)	1.35 (1.14 - 1.61)	1.36 (1.14 - 1.61)	1.42 (1.28 - 1.57)	<0.0003	0.48	1.25 (1.16 - 1.35)	<0.0003	0.39	0.05
Aromatic amino acids										
Phenylalanine	1.27 (1.07 - 1.51)	1.29 (1.04 - 1.59)	1.24 (1.04 - 1.47)	1.26 (1.14 - 1.40)	<0.0003	0.96	1.22 (1.14 - 1.31)	<0.0003	0.75	0.63
Tyrosine	1.34 (1.13 - 1.59)	1.21 (1.04 - 1.42)	1.22 (1.05 - 1.41)	1.25 (1.14 - 1.37)	<0.0003	0.64	1.21 (1.13 - 1.29)	<0.0003	0.79	0.56
Other amino acids										
Histidine	1.08 (0.91 - 1.27)	1.10 (0.91 - 1.32)	0.94 (0.80 - 1.11)	1.03 (0.93 - 1.14)	0.55	0.40	1.08 (1.00 - 1.16)	0.06	0.83	0.51
Alanine	1.35 (1.14 - 1.61)	1.15 (0.97 - 1.38)	1.27 (1.09 - 1.47)	1.26 (1.14 - 1.38)	<0.0003	0.45	1.25 (1.14 - 1.39)	<0.0003	0.19	0.96
Inflammation										
Glycoprotein acetyls	1.62 (1.38 - 1.90)	1.29 (1.05 - 1.58)	1.32 (1.15 - 1.52)	1.41 (1.28 - 1.55)	<0.0003	0.11	1.34 (1.25 - 1.43)	<0.0003	0.95	0.37
Fatty acids										

Total fatty acids	1.41 (1.22 - 1.64)	1.22 (1.03 - 1.45)	1.29 (1.12 - 1.49)	1.31 (1.20 - 1.44)	<0.0003	0.45	1.21 (1.13 - 1.29)	<0.0003	0.93	0.14
SFA (%)	1.16 (1.00 - 1.34)	1.22 (1.03 - 1.46)	1.09 (0.95 - 1.26)	1.15 (1.05 - 1.25)	0.002	0.62	1.21 (1.13 - 1.29)	<0.0003	0.56	0.36
MUFA (%)	1.52 (1.30 - 1.78)	1.48 (1.22 - 1.81)	1.32 (1.14 - 1.53)	1.43 (1.30 - 1.57)	<0.0003	0.42	1.38 (1.27 - 1.51)	<0.0003	0.28	0.63
PUFA (%)	0.66 (0.56 - 0.78)	0.67 (0.55 - 0.81)	0.78 (0.67 - 0.90)	0.71 (0.64 - 0.78)	<0.0003	0.30	0.72 (0.67 - 0.77)	<0.0003	0.48	0.78
n-6 PUFA (%)	0.64 (0.55 - 0.75)	0.68 (0.56 - 0.81)	0.76 (0.66 - 0.88)	0.70 (0.64 - 0.77)	<0.0003	0.27	0.70 (0.65 - 0.75)	<0.0003	0.52	0.96
Linoleic acid (%)	0.76 (0.65 - 0.88)	0.77 (0.65 - 0.92)	0.79 (0.68 - 0.92)	0.77 (0.71 - 0.85)	<0.0003	0.92	0.72 (0.67 - 0.77)	<0.0003	0.41	0.21
n-3 PUFA (%)	0.96 (0.83 - 1.10)	0.93 (0.78 - 1.10)	1.05 (0.90 - 1.23)	0.98 (0.89 - 1.07)	0.60	0.56	0.97 (0.91 - 1.04)	0.44	0.55	0.94
DHA (%)	0.95 (0.83 - 1.09)	0.97 (0.82 - 1.15)	1.03 (0.88 - 1.20)	0.98 (0.90 - 1.07)	0.67	0.78	0.96 (0.90 - 1.03)	0.30	0.46	0.75
Other metabolic biomarkers										
Sphingomyelins	1.01 (0.87 - 1.18)	0.92 (0.79 - 1.08)	1.07 (0.91 - 1.25)	1.00 (0.91 - 1.10)	0.98	0.44	0.90 (0.84 - 0.97)	0.007	0.70	0.08
Phosphoglycerides	1.24 (1.06 - 1.45)	1.11 (0.94 - 1.31)	1.19 (1.02 - 1.39)	1.18 (1.08 - 1.30)	<0.0003	0.60	1.08 (1.01 - 1.16)	0.03	0.67	0.14
Phosphatidylcholines	1.21 (1.04 - 1.42)	1.08 (0.92 - 1.28)	1.17 (1.01 - 1.36)	1.16 (1.06 - 1.27)	0.001	0.60	1.05 (0.98 - 1.13)	0.19	0.64	0.09
Cholines	1.15 (0.98 - 1.34)	1.03 (0.87 - 1.21)	1.14 (0.98 - 1.32)	1.11 (1.01 - 1.21)	0.03	0.58	1.02 (0.95 - 1.10)	0.63	0.71	0.16
Triglyceride by phosphoglyceride ratio	1.60 (1.37 - 1.86)	1.52 (1.24 - 1.85)	1.27 (1.11 - 1.45)	1.42 (1.30 - 1.55)	<0.0003	0.06	1.33 (1.26 - 1.42)	<0.0003	0.46	0.25
Citrate	1.15 (0.96 - 1.37)	1.05 (0.90 - 1.23)	1.38 (1.13 - 1.67)	1.16 (1.05 - 1.29)	0.003	0.11	0.91 (0.80 - 1.03)	0.13	0.11	0.00
Lactate	1.16 (0.98 - 1.37)	1.10 (0.91 - 1.34)	1.11 (0.95 - 1.29)	1.12 (1.02 - 1.24)	0.02	0.91	1.15 (0.98 - 1.35)	0.09	0.01	0.82
beta-hydroxybutyrate	1.22 (1.04 - 1.43)	1.10 (0.94 - 1.29)	1.28 (1.04 - 1.56)	1.19 (1.08 - 1.31)	0.001	0.48	0.99 (0.91 - 1.07)	0.80	0.79	0.01

Acetate	1.03 (0.84 - 1.27)	0.74 (0.50 - 1.10)	0.94 (0.81 - 1.09)	0.95 (0.85 - 1.06)	0.36	0.34	0.96 (0.88 - 1.05)	0.43	0.40	0.81
Acetoacetate	1.05 (0.91 - 1.22)	0.89 (0.74 - 1.07)	0.86 (0.73 - 1.02)	0.94 (0.86 - 1.04)	0.24	0.16	1.04 (0.96 - 1.12)	0.35	0.69	0.13
Albumin	1.28 (1.09 - 1.50)	1.26 (1.06 - 1.50)	1.17 (1.01 - 1.35)	1.23 (1.12 - 1.35)	<0.0003	0.68	1.12 (0.97 - 1.28)	0.13	0.10	0.25
Creatinine	0.96 (0.75 - 1.23)	0.71 (0.56 - 0.92)	0.96 (0.80 - 1.15)	0.89 (0.78 - 1.01)	0.07	0.14	0.97 (0.84 - 1.13)	0.72	0.06	0.36

[†]Other than fatty acids and lipoprotein measures, results for all metabolic biomarkers are shown here. For individual fatty acids, we only showed fatty acids expressed as a percentage of total fatty acids to avoid confounding by total fatty acids. All results for lipoprotein measures are displayed in Figure 1. Estimates are odds ratios (95% confidence intervals) per SD increase. The results for Chinese (n=2676), Malay (n=1872) and Indian (n=1845) participants were meta-analysed from the MEC and the SEED cohorts which consist of the Singapore Chinese Eye Study, Singapore Malay Eye Study and the Singapore Indian Eye Study. Results for the European participants (n=14558) were meta-analysed from 3 prospective Finnish cohorts (FINRISK 2002, FINRISK 2012 and Health 2000). We adjusted or matched for age, age2 (only for MEC), sex, BMI and fasting glucose (MEC and Health 2000) or HbA1c (SEED cohorts, FINRISK 2002, FINRISK 2012). We accounted for multiple testing using Bonferroni correction and P-values < 0.0003 were considered statistically significant. P-het denotes Cochran Q heterogeneity.


Abbreviations: HbA1c, glycated hemoglobin A1c, MEC, Multiethnic Cohort, MUFA, monounsaturated fatty acids, n-3, omega-3, n-6 - omega-6, PUFA, polyunsaturated fatty acids, SEED, Singapore Epidemiology of Eye Diseases, SFA, saturated fatty acids

Asians Finns


p-value < 0.0003

Asians Finns

Composite lipid measures




Lipoprotein cholesterol




Odds ratio for incident type 2 diabetes (95% CI) per 1-SD increment in metabolite concentration


Lipoprotein particle size



Apolipoproteins



Lipoprotein triglycerides



Odds ratio for incident type 2 diabetes (95% CI) per 1-SD increment in metabolite concentration